A Phase I/II Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma Relapsed From or Refractory to Bortezomib.

Trial Profile

A Phase I/II Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma Relapsed From or Refractory to Bortezomib.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 13 Oct 2009

At a glance

  • Drugs Bis-choline tetrathiomolybdate (Primary) ; Bortezomib
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Attenuon
  • Most Recent Events

    • 27 Oct 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 30 Jan 2008 The expected completion date for this trial is now 1 Dec 2008.
    • 27 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top